What formyl peptide receptors, if any, are triggered by compound 43 and lipoxin A4?

Scandinavian Journal of Immunology

Volumn 74, Issue 3, 2011, Pages 227-234

  Forsman, H ^a   Onnheim K ^a   Andreasson, E ^a   Dahlgren, C ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN; FORMYLPEPTIDE RECEPTOR 2; FORMYLPEPTIDE RECEPTOR LIKE 1; LIPOXIN A; NITROSYLATED PYRAZOLONE DERIVATIVE; PYRAZOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; DRUG BINDING; DRUG TARGETING; IN VIVO STUDY; LEUKOCYTE ACTIVATION; LEUKOCYTE FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; ARRESTINS; CALCIUM; CELL LINE, TUMOR; HL-60 CELLS; HUMANS; INFLAMMATION; LIPOXINS; MICE; NADPH OXIDASE; NEUTROPHILS; PROTEIN TRANSPORT; PYRAZOLES; REACTIVE OXYGEN SPECIES; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN; SIGNAL TRANSDUCTION;

EID: 79961120320     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2011.02570.x     Document Type: Article

References (35)

1. Dufton N, Perretti M. Therapeutic anti-inflammatory potential of formyl-peptide receptor agonists. Pharmacol Ther 2010;127:175-88.
2. Serhan CN, Brain SD, Buckley CD et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007;21:325-32.
3. Fu H, Karlsson J, Bylund J, Movitz C, Karlsson A, Dahlgren C. Ligand recognition and activation of formyl peptide receptors in neutrophils. J Leukoc Biol 2006;79:247-56.
4. Ye RD, Boulay F, Wang JM et al. International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev 2009;61:119-61.
5. Ye RD, Boulay F. Structure and function of leukocyte chemoattractant receptors. Adv Pharmacol 1997;39:221-89.
6. Rabiet MJ, Huet E, Boulay F. The N-formyl peptide receptors and the anaphylatoxin C5a receptors: an overview. Biochimie 2007;89:1089-106.
7. Stenfeldt AL, Karlsson J, Wenneras C, Bylund J, Fu H, Dahlgren C. Cyclosporin H, Boc-MLF and Boc-FLFLF are antagonists that preferentially inhibit activity triggered through the formyl peptide receptor. Inflammation 2007;30:224-9.
8. Karlsson J, Fu H, Boulay F, Bylund J, Dahlgren C. The peptide Trp-Lys-Tyr-Met-Val-D-Met activates neutrophils through the formyl peptide receptor only when signaling through the formylpeptide receptor like 1 is blocked. A receptor switch with implications for signal transduction studies with inhibitors and receptor antagonists. Biochem Pharmacol 2006;71:1488-96.
9. Heit B, Tavener S, Raharjo E, Kubes P. An intracellular signaling hierarchy determines direction of migration in opposing chemotactic gradients. J Cell Biol 2002;159:91-102.
10. Christophe T, Karlsson A, Rabiet MJ, Boulay F, Dahlgren C. Phagocyte activation by Trp-Lys-Tyr-Met-Val-Met, acting through FPRL1/LXA4R, is not affected by lipoxin A4. Scand J Immunol 2002;56:470-6.
11. Forsman H, Dahlgren C. Lipoxin A(4) metabolites/analogues from two commercial sources have no effects on TNF-alpha-mediated priming or activation through the neutrophil formyl peptide receptors. Scand J Immunol 2009;70:396-402.
12. Krishnamoorthy S, Recchiuti A, Chiang N et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A 2010;107:1660-5.
13. Key TA, Vines CM, Wagener BM, Gurevich VV, Sklar LA, Prossnitz ER. Inhibition of chemoattractant N-formyl peptide receptor trafficking by active arrestins. Traffic 2005;6:87-99.
14. Prossnitz ER. Novel roles for arrestins in the post-endocytic trafficking of G protein-coupled receptors. Life Sci 2004;75:893-9.
15. Burli RW, Xu H, Zou X et al. Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg Med Chem Lett 2006;16:3713-8.
16. Dufton N, Hannon R, Brancaleone V et al. Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol 2010;184:2611-9.
17. Forsman H, Kalderen C, Nordin A, Nordling E, Jensen AJ, Dahlgren C. Stable formyl peptide receptor agonists that activate the neutrophil NADPH-oxidase identified through screening of a compound library. Biochem Pharmacol 2011;81:402-11.
18. Sogawa Y, Shimizugawa A, Ohyama T, Maeda H, Hirahara K. The pyrazolone originally reported to be a formyl peptide receptor (FPR) 2/ALX-selective agonist is instead an FPR1 and FPR2/ALX dual agonist. J Pharmacol Sci 2009;111:317-21.
19. Sogawa Y, Ohyama T, Maeda H, Hirahara K. Formyl Peptide Receptor 1 and 2 Dual Agonist Inhibits Human Neutrophil Chemotaxis by the Induction of Chemoattractant Receptor Cross-desensitization. J Pharmacol Sci 2011;115:63-8.
20. Boyum A, Lovhaug D, Tresland L, Nordlie EM. Separation of leucocytes: improved cell purity by fine adjustments of gradient medium density and osmolality. Scand J Immunol 1991;34:697-712.
21. Itou T, Collins LV, Thoren FB, Dahlgren C, Karlsson A. Changes in activation states of murine polymorphonuclear leukocytes (PMN) during inflammation: a comparison of bone marrow and peritoneal exudate PMN. Clin Vaccine Immunol 2006;13:575-83.
22. Onnheim K, Bylund J, Boulay F, Dahlgren C, Forsman H. Tumour necrosis factor (TNF)-alpha primes murine neutrophils when triggered via formyl peptide receptor-related sequence 2, the murine orthologue of human formyl peptide receptor-like 1, through a process involving the type I TNF receptor and subcellular granule mobilization. Immunology 2008;125:591-600.
23. Dahlgren C, Christophe T, Boulay F, Madianos PN, Rabiet MJ, Karlsson A. The synthetic chemoattractant Trp-Lys-Tyr-Met-Val-DMet activates neutrophils preferentially through the lipoxin A(4) receptor. Blood 2000;95:1810-8.
24. Dahlgren C, Karlsson A. Respiratory burst in human neutrophils. J Immunol Methods 1999;232:3-11.
25. Fu H, Bjorkman L, Janmey P et al. The two neutrophil members of the formylpeptide receptor family activate the NADPH-oxidase through signals that differ in sensitivity to a gelsolin derived phosphoinositide-binding peptide. BMC Cell Biol 2004;5:50.
26. Forsman H, Dahlgren C. The FPR2-induced rise in cytosolic calcium in human neutrophils relies on an emptying of intracellular calcium stores and is inhibited by a gelsolin-derived PIP2-binding peptide. BMC Cell Biol 2010;11:52.
27. Southgate EL, He RL, Gao JL, Murphy PM, Nanamori M, Ye RD. Identification of formyl peptides from Listeria monocytogenes and Staphylococcus aureus as potent chemoattractants for mouse neutrophils. J Immunol 2008;181:1429-37.
28. Maderna P, Cottell DC, Toivonen T et al. FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. FASEB J 2011;24:4240-9.
29. Olson KR, Eglen RM. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev Technol 2007;5:137-44.
30. Zhang Q, Raoof M, Chen Y et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010;464:104-7.
31. Young SM, Bologa CM, Fara D et al. Duplex high-throughput flow cytometry screen identifies two novel formylpeptide receptor family probes. Cytometry 2009;75:253-63.
32. Schepetkin IA, Kirpotina LN, Khlebnikov AI, Quinn MT. High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists. Mol Pharmacol 2007;71:1061-74.
33. Arterburn JB, Oprea TI, Prossnitz ER, Edwards BS, Sklar LA. Discovery of selective probes and antagonists for G-protein-coupled receptors FPR/FPRL1 and GPR30. Curr Top Med Chem 2009;9:1227-36.
34. Fu H, Bylund J, Karlsson A, Pellme S, Dahlgren C. The mechanism for activation of the neutrophil NADPH-oxidase by the peptides formyl-Met-Leu-Phe and Trp-Lys-Tyr-Met-Val-Met differs from that for interleukin-8. Immunology 2004;112:201-10.
35. Chiang N, Serhan CN, Dahlen SE et al. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev 2006;58:463-87.